New research trials surrounding this compound, specifically the high-dose formulation ZPHC ZPHC, reveal a significant benefit on weight decrease and linked chronic factors. Experts anticipate that this combined acting , affecting both GLP-1 and GIP systems, could offer a major improvement in the management of obesity and related disease problems.